🇺🇸 FDA

Intelligence Platform

Patents

Browse 173 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11254913

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11246950

Combination cancer immunotherapy with pentaaza macrocyclic ring complex

Galera Labs, LLC · Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11241456

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11236139

Combination immunotherapy

The United States Government represented by the Department of Veterans Affairs · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11213592

Antibody-sting agonist conjugates and their use in immunotherapy

The Board of Regents of the University of Texas System · Granted Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11202804

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11202803

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11168303

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11168304

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11116838

Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy

Inovio Pharmaceuticals, Inc. · Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11083752

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11059880

Redirected cells with MHC chimeric receptors and methods of use in immunotherapy

Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11052116

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11052115

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11040070

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11033635

Antibody-STING agonist conjugates and their use in immunotherapy

The Board of Regents of the University of Texas System · Granted Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11013770

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue May 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11013803

Near infrared photoimmunotherapy (NIR-PIT) of suppressor cells to treat cancer

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11007226

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10993967

Combinatorial cancer immunotherapy

Senti Biosciences, Inc. · Granted Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10980868

VEGFR-2 targeting immunotherapy approach

Vaximm AG · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10983128

CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy

Providence Health & Services · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10953046

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10953047

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted